Searchable abstracts of presentations at key conferences in endocrinology

ea0031oc4.7 | Obesity, metabolism and bone | SFEBES2013

Familial hypocalciuric hypercalcaemia type 3 is caused by mutations in adaptor protein 2 sigma 1

Nesbit M Andrew , Hannan Fadil M , Howles Sarah A , Reed Anita A C , Cranston Treena , Thakker Clare E , Gregory Lorna , Rimmer Andrew J. , Rust Nigel , Graham Una , Morrison Patrick J , Hunter Steven J , Whyte Michael P , Thakker Rajesh V

Familial hypocalciuric hypercalcaemia (FHH) is an autosomal dominant disorder characterized by lifelong elevation of serum calcium concentrations with inappropriately low urinary calcium excretion. Three types referred to as FHH1, FHH2 and FHH3 and located on chromosomes 3q21.1, 19p and 19q13.3, respectively, have been reported. FHH1, caused by loss-of-function mutations of the calcium-sensing receptor (CaSR), accounts for >65% of FHH patients. To identify the gen...

ea0077oc2.4 | Endocrine Cancer and Late Effects | SFEBES2021

PBF phosphorylation regulates cell motility of thyroid and breast cancer cells

Kocbiyik Merve , Alshahrani Mohammed , Poole Vikki L , Jeyanathan Sakaorna , Thornton Caitlin , Zha Ling , Brookes Katie , Nieto Hannah , Read Martin L , McCabe Chris J , Smith Vicki E

The proto-oncogene pituitary tumor transforming gene binding factor (PTTG1IP/PBF) is overexpressed in multiple tumours and associated with tumour progression. One of the tumourigenic processes that PBF can mediate is cell motility. PBF can induce cell invasion in both thyroid and breast cancer cell lines. However, in contrast to wild-type (WT) PBF, the Y174A PBF mutant was not able to induce the invasiveness of thyroid or breast cancer cells. The Y174 residue is highly phospho...

ea0077op4.1 | Metabolism, Obesity and Diabetes | SFEBES2021

Investigating the role of the gut metabolome in appetite and obesity

Stephens Hannah , Ramgulam Anya , Franco-Becker Georgia , Tashkova Martina , Serrano Contreras Jose Ivan , Blunt Dominic , Garcia-Perez Isabel , Frost Gary , Murphy Kevin

Overweight and obesity is an escalating global health problem, affecting 40% of the population and being the 5th largest cause of death worldwide. Treatment options are limited, with pharmaceutical approaches being inadequate and the success of bariatric surgery being limited by its invasive nature. The regulation of appetite by small bioactive compounds in the gastrointestinal tract is an important target in antiobesity research. Metabolites from diet and both host and microb...

ea0078OC5.5 | Oral Communications 5 | BSPED2021

B-cell class switching in trans- and cis-gendered healthy young people is differentially influenced by sex hormones

Peckham Hannah , Rosser Elizabeth C , Radziszewska Anna , Robinson George , Martin-Gutierrez Lucia , De Gruijter Nina M , Jury Elizabeth C , Butler Gary E , Ciurtin Coziana

Cis-gender females are known to mount stronger humoral immune responses than cis-gender males. Little is known about the immunophenotypes of transgender individuals on gender-affirming hormonal treatment, despite growing evidence that hormones influence the immune system.Via the process of class-switch recombination (CSR), B-cell immunoglobulin isotype ‘switches’ from early IgM/IgD classes to IgG/IgA/IgE. Whilst important in infection/vaccine responses; switched isot...

ea0051oc7.7 | Oral Communications 7 | BSPED2017

Role of Degludec in improving diabetes outcomes in young people - An observational study from Young Diabetes Connections (YDC) Network, London

Nambisan Aparna K R , Fredriksen Samantha , Rowland Amy , Morrow Hannah , Castro-Gonzalez Marie , Ajzensztejn Michal , Hulse Tony , Lawrence Joanna , Shamekh Ahmed , Ford-Adams Martha , Chapman Simon

Introduction: YDC is a partnership of four hospital trusts;Kings College Hospital, Princess Royal University Hospital, Lewisham University Hospital and Evelina London Children’s Hospital,caring for a total of 492 children and young people with diabetes. Most young people are on conventional long acting insulin (Levemir and Glargine), but increasingly, poorly controlled patients (HbA1C>100 mmol/mol) with high admission rates are being switched to insulin Degludec due t...

ea0050oc3.6 | Obesity, Diabetes Thyroid | SFEBES2017

Identification of novel sodium iodide symporter interactors which modulate iodide uptake

Fletcher Alice , Poole Vikki , Modasia Bhavika , Imruetaicharoenchoke Waraporn , Thompson Rebecca , Sharma Neil , Nieto Hannah , Baker Katie , Alshahrani Mohammed , Read Martin , Turnell Andrew , Boelaert Kristien , Smith Vicki , McCabe Christopher

By exploiting the canonical function of the sodium iodide symporter (NIS), ablative radioiodide therapy is an effective treatment for thyroid cancer. However, a subset of patients are unable to accumulate sufficient radioiodide due to decreased expression and/or plasma membrane localisation of NIS. Radioiodide therapy has been proposed as a viable treatment for breast cancer, but is hampered by low levels of NIS membrane localisation. Currently, the regulation of NIS trafficki...

ea0050p249 | Neoplasia, Cancer and Late Effects | SFEBES2017

Multiple endocrine neoplasia type 1 (MEN1) phenocopy due to a P.Leu380Phe cell division cycle 23 (CDC73) mutation

Lines Kate E , Nachtigall Lisa B , Dichtel Laura E , Cranston Treena , Khairi Shafaq , Boon Hannah , Sagvand Babak Torabi , Zhang Xun , Stevenson Mark , Klibanski Anne , Thakker Rajesh V

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the combined occurrence of parathyroid tumours, and neuroendocrine tumours (NETs) of the pituitary and pancreas. MEN1 is caused by mutations of the tumour suppressor gene MEN1, and MEN1 germline mutations are found in >75% of MEN1 patients. The remaining 25% of patients may have mutations involving as yet unidentified gene...

ea0050p320 | Obesity and Metabolism | SFEBES2017

Androgen excess is highly prevalent in women with idiopathic intracranial hypertension and is biochemically distinct from polycystic ovary syndromes

O'Reilly Michael , Hornby Catherine , Westgate Connar , Botfield Hannah , Markey Keira , Mitchell James , Jenkinson Carl , Gilligan Lorna , Sherlock Mark , Gibney James , Tomlinson Jeremy , Arlt Wiebke , Sinclair Alexandra

Idiopathic intracranial hypertension (IIH) is a condition of unknown aetiology characterised by raised intracranial pressure, chronic headaches and blindness. Akin to polycystic ovary syndrome (PCOS), IIH patients are almost exclusively obese females of reproductive age. A distinct androgen excess profile has been noted in PCOS. Here, we aimed to delineate androgen metabolism in IIH compared to PCOS and simple obesity.Women w...

ea0050p383 | Thyroid | SFEBES2017

Novel driver mutations in thyroid cancer recurrence

Nieto Hannah , Fletcher Alice , Thompson Rebecca , Baker Kate , Alshahrani Mohammed , de Menezes Albert Nobre , Read Martin , Boelaert Kristien , Smith Vicki , Cazier Jean-Baptiste , Mehanna Hisham , McCabe Chris

Worldwide, ˜300,000 new cases of differentiated thyroid cancer are reported per annum and thyroid cancer now represents the most rapidly increasing cancer in the US and in the UK. In general terms, outcome is good (10-year survival >90%). However, up to 25% of patients develop local or regional recurrences, and have a significantly reduced life expectancy. We hypothesise those thyroid tumours which subsequently recur display a distinct pattern of driver ...

ea0050oc3.6 | Obesity, Diabetes Thyroid | SFEBES2017

Identification of novel sodium iodide symporter interactors which modulate iodide uptake

Fletcher Alice , Poole Vikki , Modasia Bhavika , Imruetaicharoenchoke Waraporn , Thompson Rebecca , Sharma Neil , Nieto Hannah , Baker Katie , Alshahrani Mohammed , Read Martin , Turnell Andrew , Boelaert Kristien , Smith Vicki , McCabe Christopher

By exploiting the canonical function of the sodium iodide symporter (NIS), ablative radioiodide therapy is an effective treatment for thyroid cancer. However, a subset of patients are unable to accumulate sufficient radioiodide due to decreased expression and/or plasma membrane localisation of NIS. Radioiodide therapy has been proposed as a viable treatment for breast cancer, but is hampered by low levels of NIS membrane localisation. Currently, the regulation of NIS trafficki...